Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary

1 day ago 4

Moby Intelligence

Thu, March 12, 2026 astatine 11:58 AM CDT 3 min read

Management characterized 2025 arsenic a pivotal foundation-building year, focusing connected improving fiscal flexibility and clarifying a semipermanent displacement toward the $10 cardinal translational subject market.
The institution is evolving from a accepted tools supplier to an enabler of translational science, aiming to span the spread betwixt carnal models and quality trials wherever 90% of cause candidates presently fail.
Q4 show was driven by a favorable premix displacement toward higher-margin merchandise lines and disciplined disbursal management, resulting successful 27% year-over-year adjusted EBITDA growth.
Strategic consolidation of manufacturing from Holliston to Minneapolis and European centers is expected to output $3 cardinal successful savings successful 2027 and $4 cardinal annually thereafter.
The institution is intentionally prioritizing higher-margin consumables, service, and software, which present correspond astir 55% of full revenue, to amended visibility and durability.
Management strengthened governance and enactment by appointing 4 caller Board members and confirming Mark Frost arsenic imperishable CFO to enactment the modulation to a platform-based exertion provider.

Full twelvemonth 2026 guidance forecasts debased single-digit gross maturation (2% to 4%) and precocious single-digit adjusted EBITDA maturation (6% to 10%), driven by higher-margin caller merchandise innovation.
Revenue is expected to ramp passim the twelvemonth connected a year-over-year percent basis, supported by stronger contributions from the NPI pipeline including SoHo telemetry and Mesh MEA.
The 2026 outlook assumes the reinstatement of worker bonuses and merit-based compensation, which were suspended successful 2025 owed to macro headwinds.
Management expects a affirmative interaction from the February NIH backing support to statesman appearing successful orders precocious successful Q1, with superior gross benefits realized successful Q2.
The institution plans to proceed deleveraging done a indebtedness operation that requires nary amortization successful the archetypal 2 years and offers imaginable conversion of indebtedness to equity.

A 43-day authorities shutdown during the 4th fourth impacted the company's quality to overachieve connected gross targets.
Full twelvemonth GAAP operating income was importantly impacted by a goodwill impairment complaint taken earlier successful 2025.
The institution successfully remediated worldly weaknesses and 1 important deficiency successful its fiscal reporting during the year.
A broad refinancing completed successful December extended indebtedness maturity to 2021 and reduced yearly indebtedness work by $3 cardinal for the archetypal 2 years.